Pharmacy and Poisons Board — Kenya's medicines regulator, leading enforcement against counterfeit drugs and approving new pharmaceuticals in the market.
… Days after recent revelations on expired HIV drugs and fake medications in public hospital stores, the Pharmacy and Poisons Board has issued fresh alerts regarding counterfeit Postinor-2 emergency contraceptives. …
… Audio By Vocalize The Pharmacy and Poisons Board (PPB) has approved seven new semaglutide-based medicines in Kenya, expanding treatment options for people living with type 2 diabetes as demand for the drugs continues to rise. …
… The Pharmacy and Poisons Board (PPB) raised the alarm after identifying falsified Postinor-2 (Levonorgestrel 0.75mg tablets), warning that the medicine may contain incorrect amounts of the active ingredient, no active ingredient at all, harmful contaminants or undeclared substanc …
Pharmacy and Poisons Board issues alert on circulation of 'fake' P2 pills in Kenya By Kenneth Gachie August 14, 2026 11:03 (EAT) Add as a Preferred Source on Google Follow us Follow on Whatsapp Follow on Google Follow on Twitter A photo of a box containing P2 pills. …
Audio By VocalizeThe Pharmacy and Poisons Board has warned the public against a fake batch of Postinor-2 (P2) tablets circulating in the Kenyan market. …
… In Kenya, this responsibility is entrusted to the Pharmacy and Poisons Board, the national medicines regulatory authority established under the Pharmacy and Poisons Act (Cap. …
… In Kenya, this responsibility is entrusted to the Pharmacy and Poisons Board, the national medicines regulatory authority established under the Pharmacy and Poisons Act (Cap. …
… He noted that the Pharmacy and Poisons Board (PPB) has the mandate to regulate all medical products and ensure they meet the highest standards of safety, quality and efficacy. …
The Pharmacy and Poisons Board has issued alerts about counterfeit Postinor-2 emergency contraceptives circulating in Kenya's market, part of a broader problem of sub-standard, expired, and fake medicines in hospital and pharmacy stores. The opinion argues that regulatory enforcement, port health authorities, and customs control mechanisms have failed in oversight, allowing counterfeit drugs to reach local chemists.
The Pharmacy and Poisons Board has issued alerts about counterfeit Postinor-2 emergency contraceptives circulating in Kenya's market, part of a broader problem of sub-standard, expired, and fake medicines in hospital and pharmacy stores. The opinion argues that regulatory enforcement, port health authorities, and customs control mechanisms have failed in oversight, allowing counterfeit drugs to reach local chemists.
Kenya is implementing a medicine tracking system to combat counterfeit drugs. The Pharmacy and Poisons Board is leading efforts to tighten control over pharmaceuticals in the market.
The Pharmacy and Poisons Board has approved seven semaglutide-based medicines in Kenya, expanding treatment options for type 2 diabetes. Although the products share the same active ingredient, they do not necessarily have the same approved uses, and the regulator has warned the public against using semaglutide medicines without medical supervision, particularly for weight loss.
The Pharmacy and Poisons Board has alerted the public to falsified Postinor-2 emergency contraceptive pills circulating in Kenya, warning that the counterfeits may contain incorrect or no active ingredient, harmful contaminants, or undeclared substances, potentially failing to prevent unintended pregnancies. The affected batch is Postinor-2, Batch No. T34197R, falsely claimed to be manufactured by Gedeon Richter, and can be distinguished from genuine products by printing differences, carton-sealing methods, and altered logo fonts on the authentication panel.
The Pharmacy and Poisons Board has warned of a falsified batch of Postinor-2 (emergency contraceptive) pills circulating in Kenya, identified as Batch Number T34197R. The counterfeit product differs from genuine pills in batch printing method, carton sealing, and patient information leaflet quality.
The Pharmacy and Poisons Board has alerted the public to a fake batch of Postinor-2 (Levonorgestrel 0.75mg), batch number T34197R, falsely claiming manufacture by Gedeon Richter Plc. The counterfeit product differs from genuine stock in packaging, sealing, and printing methods, and may contain incorrect or no active ingredient, harmful contaminants, or undeclared substances.
The article argues that medicines regulation is essential to public health, ensuring patients receive safe, effective, and quality products through evaluation, manufacturing standards, secure supply chains, and post-market monitoring, particularly as Kenya advances Universal Health Coverage.
An opinion piece argues that safe, effective medical products depend on rigorous regulatory processes—evaluation before market entry, manufacturing standards, secure supply chains, and post-market monitoring—which are essential as Kenya advances Universal Health Coverage.
Health Cabinet Secretary Aden Duale announced plans to ban the delivery of antibiotics through boda boda riders as part of efforts to combat counterfeit medicines and illegal online sales of prescription drugs, stating that prescription drugs should only be dispensed through licensed pharmacies.
Japan has committed KSh3 billion to support Kenya's local vaccine manufacturing programme, with the funding to be channelled through the State Department for Medical Services and KEMRI to strengthen research infrastructure and skills development.
The government has closed more than 200 non-compliant pharmaceutical premises as part of an enforcement campaign against counterfeit and substandard medicines. Health Cabinet Secretary Aden Duale said fake drugs undermine treatment outcomes and public confidence in healthcare services, and the Pharmacy and Poisons Board has intensified surveillance, product recalls, and public alerts.
The Pharmacy and Poisons Board has warned that counterfeit and substandard medicines—including male sexual enhancement drugs, HIV testing kits, and blood thinners—continue to circulate in Kenya. Between 2021 and 2025, the board received 1,413 complaints about health product quality and recalled 99 products from the market.
The Pharmacy and Poisons Board has warned that counterfeit medical products including viagra, HIV rapid diagnostic test kits, and dialysis medications are circulating in Kenya, raising patient safety concerns. Between 2021 and 2025, the regulator received 1,413 product quality complaints resulting in 99 medical product recalls.
Kenya's AI Bill 2026, which received its first Senate reading in April, and new Pharmacy and Poisons Board guidelines for medical device software will set compliance requirements for pharmacies, clinics, hospitals, and digital health businesses. The AI Bill classifies AI-assisted medical devices as high-risk, requiring risk assessments, human rights impact assessments, data retention, and compliance reporting, with penalties up to Sh5 million or two years' imprisonment for breaches.
Kenya is working to achieve WHO Maturity Level 3 (ML3) status in pharmaceutical regulation by December this year, which the Ministry of Health says would strengthen oversight of medical products, boost local manufacturing, and improve access to safe and effective medicines. Attaining ML3 status would place Kenya among a select group of African nations with stable and well-functioning regulatory systems.
The Pharmacy and Poisons Board arrested 95 individuals and shut down 48 unlicensed medicine outlets during a week-long enforcement operation across Nairobi and Kajiado counties. The closures followed inspections of 155 pharmaceutical premises that uncovered widespread violations of pharmaceutical regulations.
The Pharmacy and Poisons Board arrested 95 people and shut down 48 unlicensed pharmaceutical premises following a week-long crackdown across Nairobi's informal settlements and Kajiado County, inspecting 155 premises and seizing approximately 169 cartons of medicines.
Health Cabinet Secretary Aden Duale met with senior WHO officials during the World Health Summit Regional Meeting 2026 in Nairobi to discuss global health cooperation, regional health security, and Kenya's health sector reforms under the Bottom-Up Economic Transformation Agenda, including Universal Health Coverage, local pharmaceutical manufacturing, and Africa's role in global health diplomacy.